Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Pola-G-Len for R/R follicular lymphoma

Catherine Diefenbach • 1 Jul 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Lenalidomide Obinutuzumab Polatuzumab vedotin

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the interim analysis of the Phase Ib/II study of polatuzumab vedotin, obinituzumab and lenalidomide for relapsed/refractory follicular lymphoma (NCT02600897). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Catherine Diefenbach

6:45
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
Catherine Diefenbach • 11 Dec 2023
1:34
How will bispecifics impact the treatment of NHL?
Catherine Diefenbach • 11 Dec 2022
2:31
Long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in R/R FL
Catherine Diefenbach • 11 Dec 2022
1:30
Advances in the management of R/R Hodgkin lymphoma
Catherine Diefenbach • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals